E.V. BOBYKIN

Ural State Medical University of the Ministry of Healthcare of the Russian Federation, 3 Repina Str., Yekaterinburg, Russian Federation, 620028

  Bobykin E.V. — Cand. Med. Sc., Associate Professor of the Department of Ophthalmology, tel. (343) 214 80 00, e-mail: oculist.ev@gmail.com.

 Abstract. The review presents current literature data on the anti-angiogenic therapy of macular disorders. Information on all existing anti-VEGF agents is given with an emphasis on Ranibizumab and Aflibercept registered in Russia. Different treatment regimens are considered, including the most common in everyday practice, “as needed” (Pro Re Nata, PRN) and “treat-and-extend” (T&E) with an analysis of the advantages and disadvantages of each. The regime that allows to achieve optimal treatment results with the minimum number of injections and visits must be effective, proactive, individualized and convenient. The closest to these criteria today is T&E. The most important task is to approximate the results obtained in real clinical practice to the data of clinical studies. To improve the direction, further clinical research (including real practice) is needed, as well as the study of life quality and adherence of patients to treatment.

 Key words: anti-VEGF therapy, regimen, fixed mode, “as needed” (PRN), “treat-and-extend” (T&E).

(For citation: Bobykin E.V. Anti-angiogenic therapy for treatment of macular disorders in ophthalmology. Literature review. Practical Medicine. 2018)

REFERENCES

1. Ishikawa M., Jin D., Sawada Y. et al. Future therapies of wet age-related macular degeneration. Journal of ophthalmology, 2015, vol. 2015: 138070. doi: 10.1155/2015/138070. Epub. 2015, Feb 24.
2. Neroev V.V. Russian observational epidemiological non-interventional study of patients with a wet form of age-related macular degeneration. Rossiyskiy oftal’mologicheskiy zhurnal, 2011, vol. 4, no. 2, pp. 4–9 (in Russ.).
3. Wolf S. Diabetic macular oedema and the importance of vascular endothelial growth factor therapies in its treatment. Eur Ophthalmic Rev, 2014, vol. 8, pp. 53–60.
4. Rogers S., McIntosh R. L., Cheung N. et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology, 2010, vol. 117, no. 2, pp. 313–319.
5. Wong W.L., Su X., Li X. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global Health, 2014, vol. 2, no. 2, pp. e106–e116.
6. Klein R., Knudtson M. D., Lee K. E. et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology, 2009, vol. 116, no. 3, pp. 497–503.
7. Brown D.M., Kaiser P.K., Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine, 2006, vol. 355, no. 14, pp. 1432–1444.
8. Boyko E.V. et al. Antiangiogennaya terapiya v oftal’mologii [Antiangiogenic therapy in ophthalmology]. Saint Petersburg, V MedA im. C.M. Kirova, 2013. 292 p.
9. Ford J.A., Lois N., Royle P. et al. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ open, 2013, vol. 3, no. 3, p. e002269.
10. Lövestam‐Adrian M., Agardh E. Photocoagulation of diabetic macular oedema; complications and visual outcome. Acta Ophthalmologica Scandinavica: Clinical Science, 2000, vol. 78, no. 6, pp. 667–671.
11. Freund K.B., Mrejen S., Gallego-Pinazo R. An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert opinion on pharmacotherapy, 2013, vol. 14, no. 8, pp. 1017–1028.
12. Usui T., Ishida S., Yamashiro K. et al. VEGF164 (165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Investigative ophthalmology & visual science, 2004, vol. 45, no. 2, pp. 368–374.
13. Ahmadi M.A., Lim J.I. Pharmacotherapy of age-related macular degeneration. Expert opinion on pharmacotherapy, 2008, vol. 9, pp. 3045–3052.
14. Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nature medicine, 2010, vol. 16, no. 10, pp. 1107–1111.
15. Rosenfeld P.J., Fung A.E., Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion. Ophthalmic Surgery, Lasers and Imaging Retina, 2005, vol. 36, no. 4, pp. 336–339.
16. Moja L., Lucenteforte E., Kwag K. H. et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. The Cochrane database of systematic reviews, 2014, vol. 9, p. CD011230.
17. Martin D., Maguire M., Fine S.L. et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology, 2012, vol. 119, no. 7, pp. 1388–1398.
18. Kodjikian L., Decullier E., Souied E.H. et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2014, vol. 252, no. 10, pp. 1529–1537.
19. VEGF Trap-Eye (aflibercept ophthalmic solution) briefing document. Ophthalmologic Drugs Advisory Committee. June 17, 2011. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2011, available at: http://investor.regeneron.com/releasedetail.cfm?releaseid=585837 (accessed: 13.08.2018).
20. Papadopoulos N., Martin J., Ruan Q. et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 2012, vol. 15, no. 2, pp. 171–185.
21. Stewart M. W. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert review of clinical pharmacology, 2014, vol. 7, no. 2, pp. 167–180.
22. Rakic J. M., Lambert V., Devy L. et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Investigative ophthalmology & visual science, 2003, vol. 44, pp. 3186–93.
23. Hoeben A., Landuyt B., Highley M. S. et al. Vascular endothelial growth factor and angiogenesis. Pharmacological reviews, 2004, vol. 56, no. 4, pp. 549–580.
24. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.-F. et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology, 2014, vol. 121, no. 1, pp. 193–201.
25. DRCRnet, Wells J. A., Glassman A. R. et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology, 2016, vol. 123, no. 6, pp. 1351–1359.
26. Heier J.S., Korobelnik J.F., Brown D.M. et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology, 2016, vol. 123, no. 11, pp. 2376–2385.
27. Heier J.S., Clark W.L., Boyer D.S. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology, 2014, vol. 121, no. 7, pp. 1414–1420.
28. Ogura Y., Roider J., Korobelnik J. F. et al. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. American journal of ophthalmology, 2014, vol. 158, no. 5, pp. 1032–1038.
29. Clark W. L., Boyer D. S., Heier J. S. et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology, 2016, vol. 123, no. 2, pp. 330–336.
30. Ikuno Y., Ohno-Matsui K., Wong T. Y. et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology, 2015, vol. 122, no. 6, pp. 1220–1227.
31. Okhotsimskaya T.D., Zaytseva O.V. Aflibercept in the treatment of retinal diseases. Review of clinical studies. Rossiyskiy oftal’mologicheskiy zhurnal, 2017, vol. 10, no. 2, pp. 103–111 (in Russ.).
32. Lu X., Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug design, development and therapy, 2015, vol. 9, pp. 2311–2320.
33. Sun Z., Zhou H., Lin B. et al. Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion. Retina (Philadelphia, Pa.), 2017, vol. 37, no. 9, pp. 1723–1730.
34. Singh R.P. 2018 Global Trends in Retina Survey Sistem. Trebovaniya: Adobe Acrobat Reader, available at: https://www.asrs.org/content/documents/2018-global-trends-in-retina-survey-highlights-website.pdf (accessed: 13.08.2018).
35. García-Layana A., Figueroa M.S., Araiz J. et al. Treatment of exudative age-related macular degeneration: focus on aflibercept. Drugs & aging, 2015, vol. 32, no. 10, pp. 797–807.
36. Kovach J. L., Schwartz S. G., Flynn H. W. et al. Anti-VEGF treatment strategies for wet AMD. Journal of ophthalmology, 2012, vol. 2012.:786870.
37. Brown D.M., Michels M., Kaiser P.K. et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology, 2009, vol. 116, no. 1, pp. 57–65.
38. Rosenfeld P.J., Brown D.M., Heier J.S. et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 2006, vol. 355, no. 14, pp. 1419–1431.
39. Holz F.G., Tadayoni R., Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology, 2015, vol. 99, no. 2, pp. 220–226.
40. Feltgen N., Bertelmann T., Bretag M. et al. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2017, vol. 255, no. 5, pp. 923–934.
41. Schmidt-Erfurth U., Eldem B., Guymer R. et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology, 2011, vol. 118, no. 5, pp. 831–839.
42. Regillo C.D., Brown D.M., Abraham P. et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. American journal of ophthalmology, 2008, vol. 145, no. 2, pp. 239–248.
43. Roach L. Treat-and-Extend Strategy: Is There a Consensus? EyeNet Magazine. January, 2016, available at: https://www.aao.org/eyenet/article/treat-extend-strategy-is-there-consensus (accessed: 13.08.2018).
44. Ikemori S., Kato A., Yasukawa T. et al. Effect of a single-dose regimen of intravitreal ranibizumab in the treatment of neovascular age-related macular degeneration. J Clin Exp Ophthalmol, 2012, vol. 3, no. 221, p. 2.
45. Carneiro A.M., Mendonça L.S., Falcão M.S. et al. Comparative study of 1+ PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology (Auckland, NZ), 2012, vol. 6, pp. 1149.
46. Korotkikh S.A., Bobykin E.V. Miopicheskaya makulopatiya: metod. Rekomendatsii [Myopic maculopathy: method. recommendations]. Ekaterinburg: Izd-vo UGMU, 2017. 64 p.
47. Ulitina A.Yu. Otsenka klinicheskoy effektivnosti ranibizumaba pri razlichnykh formakh vlazhnoy vozrastnoy makulyarnoy degeneratsii: avtoreferat dis. … kand. med. nauk [Evaluation of the clinical efficacy of ranibizumab in various forms of wet age-related macular degeneration. Synopsis of dis. PhD med. sciences]. Saint Petersburg, 2014. 22 p.
48. Patel A.V., Barb S.M., Young L.H. Finding the optimal treatment plan for exudative AMD: a review of current anti-VEGF dosing regimens. International ophthalmology clinics, 2015, vol. 55, no. 4, pp. 103–112.
49. Korotkikh S.A., Bobykin E.V., Nazarova N.S. et al. Antiangiogenic therapy for neovascular diseases of the macular region (long-term results). Vestnik oftal’mologii, 2016, vol. 132, no. 1, pp. 76–84 (in Russ.).
50. Engelbert M., Zweifel S.A., Freund K.B. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina, 2010, vol. 30, no. 9, pp. 1368–1375.
51. Gupta O.P., Shienbaum G., Patel A.H. et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology, 2010, vol. 117, no. 11, pp. 2134–2140.
52. Oubraham H., Cohen S.Y., Samimi S. et al. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration. Retina, 2011, vol. 31, no. 1, pp. 26–30.
53. Toalster N., Russell M., Paul N.G. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina, 2013, vol. 33, no. 7, pp. 1351–1358.
54. Freund K.B., Korobelnik J.F., Devenyi R. et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina, 2015, vol. 35, no. 8, pp. 1489–1506.
55. Lanzetta P., Loewenstein A., Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2017, vol. 255, no. 7, pp. 1259–1273.
56. Yonekawa Y., Andreoli C., Miller J. B. et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. American journal of ophthalmology, 2013, vol. 156, no. 1, pp. 29–35.
57. Stone T. W. ASRS 2016 Preferences and Trends Membership Survey: Chicago, IL. American Society of Retina Specialists; 2016, available at: https://www.asrs.org/asrs-community/pat-survey (accessed: 13.08.2018).
58. Rush R.B., Simunovic M.P., Aragon A.V. 2nd et al. Treat-and-extend intravitreal bevacizumab for branch retinal vein occlusion. Ophthalmic Surgery, Lasers and Imaging Retina, 2014, vol. 45, no. 3, pp. 212–216.
59. Ebneter A., Waldmeier D., Zysset-Burri D. C. et al. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. Graefe’s archive for clinical and experimental ophthalmology, 2017, vol. 255, no. 3, pp. 549–555.
60. Arias L., Roman I., Masuet-Aumatell C. et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina, 2011, vol. 31, no. 7, pp. 1261–1267.
61. Mone´s J., Biarnes M., Trindade F. et al. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefe’s Archive for Clinical and Experimental Ophthalmology, 2012, vol. 250, no. 12, pp. 1737–1744.
62. Lala C., Framme C., Wolf-Schnurrbusch U. E. et al. Three‐year results of visual outcome with disease activity–guided ranibizumab algorithm for the treatment of exudative age‐related macular degeneration. Acta ophthalmologica, 2013, vol. 91, no. 6, pp. 526–530.
63. Gianniou C., Dirani A., Ferrini W. et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye, 2015, vol. 29, no. 3, p. 342.
64. Mantel I., Niderprim S. A., Gianniou C. et al. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. British journal of ophthalmology, 2014, vol. 98, pp. 1192–1196.
65. Instruktsiya po meditsinskomu primeneniyu preparata “Eylea”. Registratsionnyy nomer: LP-003544-200117 [Instructions for the medical use of the drug «Eilea». Registration number: LP-003544-200117].
66. Lip P.L., Cikatricis P., Sarmad A. et al. Efficacy and timing of adjunctive therapy in the anti-VEGF treatment regimen for macular oedema in retinal vein occlusion: 12-month real-world result. Eye, 2018, vol. 32, no. 3, pp. 537–545.
67. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata “Lutsentis”. Registratsionnyy nomer: LSR-004567/08-270417 [Instructions for the medical use of the drug «Lucentis». Registration number: LSR-004567 / 08-270417].
68. LUCENTIS® (ranibizumab injection) for intravitreal injection: full prescribing information, available at: https://www.gene.com/patients/medicines/lucentis (accessed: 13.08.2018).
69. Bobykin E.V., Morozova O.V., Buslaev R.V. Estimation of the duration of anti-angiogenic therapy of macula diseases in real clinical practice. Prakticheskaya meditsina, 2017, vol. 2, no. 9 (110), pp. 43–48 (in Russ.).